Related references
Note: Only part of the references are listed.Arginine Metabolism and Its Potential in Treatment of Colorectal Cancer
Tao Du et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2021)
Comparison of the molecular and cellular phenotypes of common mouse syngeneic models with human tumors
Wenyan Zhong et al.
BMC GENOMICS (2020)
Cancer statistics, 2020
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2020)
Single-Cell Analyses Inform Mechanisms of Myeloid-Targeted Therapies in Colon Cancer
Lei Zhang et al.
CELL (2020)
Regorafenib and Nivolumab or Pembrolizumab Combination and Circulating Tumor DNA Response Assessment in Refractory Microsatellite Stable Colorectal Cancer
Chongkai Wang et al.
ONCOLOGIST (2020)
The Efficacy and Safety of Regorafenib in Combination With Anti-PD-1 Antibody in Refractory Microsatellite Stable Metastatic Colorectal Cancer: A Retrospective Study
Jisheng Li et al.
FRONTIERS IN ONCOLOGY (2020)
The Role of Dynamic ctDNA Monitoring During Combination Therapies of BRAF V600E-Mutated Metastatic Colorectal Cancer: A Case Report
Zhan Wang et al.
ONCOTARGETS AND THERAPY (2020)
Advances in immunotherapy for colorectal cancer: a review
Gol Golshani et al.
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY (2020)
Immunotherapy of colorectal cancer: Challenges for therapeutic efficacy
Davide Ciardiello et al.
CANCER TREATMENT REVIEWS (2019)
Macrophages and Metabolism in the Tumor Microenvironment
Ilio Vitale et al.
CELL METABOLISM (2019)
Third- or Later-line Therapy for Metastatic Colorectal Cancer: Reviewing Best Practice
Tanios Bekaii-Saab et al.
CLINICAL COLORECTAL CANCER (2019)
Update on systemic therapy for colorectal cancer: biologics take sides
Olumide Gbolahan et al.
TRANSLATIONAL GASTROENTEROLOGY AND HEPATOLOGY (2019)
Dinaciclib induces immunogenic cell death and enhances anti-PD1-mediated tumor suppression
Dewan Md Sakib Hossain et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
Targeting immune checkpoints potentiates immunoediting and changes the dynamics of tumor evolution
Mirjana Efremova et al.
NATURE COMMUNICATIONS (2018)
Anti-PD-1 therapy redirects macrophages from an M2 to an M1 phenotype inducing regression of OS lung metastases
Pooja Dhupkar et al.
CANCER MEDICINE (2018)
Impact of L-Arginine Metabolism on Immune Response and Anticancer Immunotherapy
Sun-Hee Kim et al.
FRONTIERS IN ONCOLOGY (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Evaluation of classical clinical endpoints as surrogates for overall survival in patients treated with immune checkpoint blockers: a systematic review and meta-analysis
Howard L. Kaufman et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2018)
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
Jordi Bruix et al.
LANCET (2017)
PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity
Sydney R. Gordon et al.
NATURE (2017)
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Dung T. Le et al.
SCIENCE (2017)
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
E. Van Cutsem et al.
ANNALS OF ONCOLOGY (2016)
A Phase II Efficacy and Safety, Open-Label, Multicenter Study of Imprime PGG Injection in Combination With Cetuximab in Patients With Stage IV KRAS-Mutant Colorectal Cancer
Neil H. Segal et al.
CLINICAL COLORECTAL CANCER (2016)
Pharmacologic activity and pharmacokinetics of metabolites of regorafenib in preclinical models
Dieter Zopf et al.
CANCER MEDICINE (2016)
Antitumor activity of the multikinase inhibitor regorafenib in patient-derived xenograft models of gastric cancer
Hung Huynh et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2015)
VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors
Thibault Voron et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2015)
Overcoming T cell exhaustion in infection and cancer
Kristen E. Pauken et al.
TRENDS IN IMMUNOLOGY (2015)
Colorectal cancer
Ernst J. Kuipers et al.
NATURE REVIEWS DISEASE PRIMERS (2015)
Immunomic, genomic and transcriptomic characterization of CT26 colorectal carcinoma
John C. Castle et al.
BMC GENOMICS (2014)
Macrophage Activation and Polarization: Nomenclature and Experimental Guidelines
Peter J. Murray et al.
IMMUNITY (2014)
Regorafenib (BAY 73-4506): Antitumor and antimetastatic activities in preclinical models of colorectal cancer
Roberta Schmieder et al.
INTERNATIONAL JOURNAL OF CANCER (2014)
VEGFA-VEGFR Pathway Blockade Inhibits Tumor-Induced Regulatory T-cell Proliferation in Colorectal Cancer
Magali Terme et al.
CANCER RESEARCH (2013)
Deciphering and Reversing Tumor Immune Suppression
Greg T. Motz et al.
IMMUNITY (2013)
Regorafenib Inhibits Growth, Angiogenesis, and Metastasis in a Highly Aggressive, Orthotopic Colon Cancer Model
Lotfi Abou-Elkacem et al.
MOLECULAR CANCER THERAPEUTICS (2013)
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial
George D. Demetri et al.
LANCET (2013)
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
Axel Grothey et al.
LANCET (2013)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity
Scott M. Wilhelm et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
Non-invasive assessment of vessel morphology and function in tumors by magnetic resonance imaging
Fabian Kiessling et al.
EUROPEAN RADIOLOGY (2007)
Share Paper
